Partner with a Medical Device CRO specialized in Software as a Medical Device (SaMD) clinical trials and evaluations. We support SaMD evidence generation through clinical study design, evaluation planning, and usability assessment aligned with regulatory expectations. Our approach ensures robust, traceable data to demonstrate safety, performance, and clinical value across the SaMD lifecycle.
Medical device software classification is the process of categorizing software based on its intended use, risk to patients, and impact on clinical decisions. Proper classification determines the level of regulatory oversight, the type of documentation required, and the pathway for market approval.
ProRelix Research provides expert support for medical device software classification, helping developers determine the correct risk class for their software. This guidance ensures that your SaMD or medical software complies with global regulations and meets regulatory expectations for clinical trials, evaluation, and market approval.
Class I: Low-risk devices with minimal potential for harm. Usually subject to general controls.
Class II: Moderate-risk devices requiring special controls, such as performance standards, post-market surveillance, or clinical data.
Class III: High-risk devices that support or sustain life, prevent impairment, or pose significant risk. Typically require Premarket Approval (PMA).
Under the Medical Device Regulation (MDR 2017/745), software is classified according to its intended purpose and risk. Classification levels determine whether the software can be self-certified or requires assessment by a Notified Body. High-risk software impacting critical clinical decisions undergoes strict conformity assessment.
The IMDRF SaMD Risk Classification Framework categorizes software based on two dimensions:
Significance of the information provided (inform, drive, or treat/diagnose)
State of the healthcare situation or condition (non-serious, serious, or critical)
This framework ensures a globally harmonized approach to risk-based classification.
Health Canada classifies medical device software using a four-class system (Class I to IV) based on risk.
TGA (Australia) follows risk-based classification aligned with international standards.
Software as a Medical Device guidelines outline recommended best practices for developing, validating, clinically evaluating, and maintaining medical software throughout its lifecycle. These guidelines focus on defining intended use, applying risk based classification, generating appropriate clinical evidence, implementing quality and risk management systems, ensuring cybersecurity and data integrity, and conducting post market performance monitoring. While not legally binding, SaMD guidelines help manufacturers align with regulatory expectations and demonstrate safety, effectiveness, and ongoing compliance across global markets.
ProRelix Research helps sponsors interpret and apply Software as a Medical Device guidelines through structured clinical evaluation, evidence planning, and regulatory aligned trial execution. With a strong focus on data integrity, risk based assessment, and compliant reporting, we supports the development of SaMD solutions that meet global expectations for safety, performance, and reliability.
Clearly define the medical function of the software, such as diagnosis, monitoring, prediction, or treatment, as this determines regulatory applicability and risk level.
Classify the SaMD according to its impact on patient health and clinical decision making, following recognized frameworks such as IMDRF.
Implement a quality management system aligned with ISO 13485 to control design, development, testing, documentation, and change management activities.
Demonstrate safety and performance through analytical validation, clinical performance studies, and real world evidence, as appropriate to the risk class.
Follow a documented software lifecycle process that includes design controls, verification, validation, version control, and configuration management.
Apply ISO 14971 principles to identify and mitigate risks, including cybersecurity threats, data privacy, and system failures.
Align development and clinical activities with applicable regulatory frameworks such as FDA requirements, EU MDR or IVDR, and regional market regulations.
Establish processes to monitor safety, effectiveness, and user feedback after market release to support continuous compliance and improvement.
Software as a Medical Device Regulations set the framework to ensure that medical software is safe, effective, and compliant with global standards. Navigating these rules can be complex, which is where ProRelix Research comes in as a leading CRO for Software as a Medical Device Clinical Trial / Evaluation. We help SaMD developers plan studies, conduct usability testing, manage risks, and generate strong clinical evidence, making sure your software meets regulatory expectations while demonstrating real-world performance and value.
In practice, FDA guidance for SaMD emphasizes:
Software as a Medical Device (SaMD) Labeling Requirements are critical to ensuring compliance with global regulatory standards and ensuring that the software is safe, effective, and ready for market use. These requirements typically include clear labeling for intended use, version updates, user instructions, warnings, manufacturer information, and performance limitations. It is essential for manufacturers to follow these regulations to meet safety standards and avoid costly compliance issues. ProRelix Research provides expert support in navigating Software as a Medical Device Labeling Requirements, helping you ensure that your software meets all necessary guidelines for market approval.
The label must clearly define the intended medical purpose of the software. This includes what the software is meant to do (e.g., diagnosis, monitoring, treatment) and any specific conditions or diseases it addresses. The intended use must align with the software’s clinical claims and regulatory submission.
The version number of the software must be clearly labeled to identify the specific release being used. If updates or new versions of the software are available, the label should indicate how users can access them. This is important for tracking changes and ensuring that the most up-to-date version is being used.
A clear set of instructions for use (IFU) must be provided. These instructions should include:
How to install and operate the software
Safety precautions and limitations
Troubleshooting guidance
How to ensure optimal performance
The label should include any warnings, precautions, or contraindications to ensure user safety. This may include information about potential risks, such as incorrect diagnosis or data privacy concerns.
The label must provide the manufacturer’s name, contact details, and any regulatory approval numbers (such as FDA registration or CE mark). This is essential for traceability and accountability.
The software label should include any relevant regulatory compliance statements, such as adherence to specific standards like ISO 13485 (quality management) or ISO 14971 (risk management). It should also indicate if the software complies with local regulatory bodies (e.g., FDA, EMA, Health Canada).
Since SaMD often deals with sensitive health data, the label should provide information about the software’s data security measures, privacy policy, and any applicable data protection regulations (such as GDPR in Europe or HIPAA in the U.S.).
The label must clearly explain any performance limitations of the software, including what the software cannot do or scenarios where it might fail to deliver accurate results.
For SaMD to function correctly, the label should specify the platform or devices the software is compatible with (e.g., specific operating systems, hardware requirements, or integration capabilities).
The label should include instructions on how users can report issues or provide feedback. It may also contain a link or reference to where the user can access post-market surveillance data, product updates, or support services.
Software as a Medical Device (SaMD) refers to software that is intended to perform medical purposes, such as diagnosis, monitoring, or treatment, without being part of a physical medical device. Certification for SaMD ensures that the software meets the necessary safety, performance, and regulatory standards set by authorities like the FDA, EMA, or Health Canada, making it eligible for use in medical settings.
ProRelix Research provides expert guidance and support throughout the Software as a Medical Device certification process, helping developers navigate complex regulatory requirements. From clinical evaluations to quality management systems and regulatory submissions, ProRelix Research ensures that your SaMD is certified, compliant, and ready for market.
The first step in obtaining SaMD certification is determining the appropriate regulatory pathway. Depending on the software’s intended use and potential risk to patients, it may fall under different regulatory categories, such as Class I, II, or III in the FDA framework.
Conducting a comprehensive risk assessment is a crucial part of the certification process. SaMD developers must evaluate risks related to software failures, data privacy, and patient safety, following standards like ISO 14971 for risk management.
SaMD developers must provide clinical evidence that demonstrates the software's safety and effectiveness. This may involve clinical trials or the collection of real-world data that supports the intended use of the software.
Adhering to a robust Quality Management System (QMS), such as ISO 13485, is essential for SaMD certification. This ensures that the software development process meets regulatory standards, including design, testing, validation, and post-market surveillance. responsibilities in clinical trials. It clearly documents accountability for trial management, regulatory reporting, safety oversight, and compliance activities. Accurate and timely completion ensures FDA acknowledgment of responsibility changes and supports transparent regulatory operations for sponsors and CROs, which is specialy critical for high risk or complex 510(k), PMA, and De Novo clinical trials conducted under FDA oversight.!
Once the necessary clinical and quality data is collected, SaMD developers submit the required documentation to regulatory authorities for review. For instance, in the U.S., developers may need to file a 510(k) notification or a Premarket Approval (PMA) application with the FDA.
After receiving certification, post-market surveillance is crucial for monitoring the software’s performance in real-world clinical settings. This helps identify potential safety issues or areas for improvement in the software’s design and functionality.
Medical device regulatory consulting provides expert guidance to manufacturers, including those developing Software as a Medical Device (SaMD), to ensure compliance with global regulatory requirements. This consulting covers regulatory strategy development, helping companies identify the correct pathways based on device classification and intended use. It includes compliance assessment against regulations such as FDA 21 CFR, EU MDR/IVDR, and ISO standards, as well as support in preparing submissions like 510(k), PMA, and CE marking. Additionally, regulatory consulting addresses quality management system implementation, risk management, post-market surveillance, and vigilance reporting. ProRelix Research offers professional medical device regulatory consulting, helping manufacturers navigate complex regulations, streamline approvals, and maintain safety, quality, and compliance across global markets.
The software as a medical device framework defines how medical software is designed, validated, clinically evaluated, regulated, and monitored throughout its lifecycle. It covers intended use definition, risk classification, quality management, clinical evidence generation, cybersecurity, data integrity, regulatory compliance, and post market performance monitoring. This framework ensures that SaMD products are safe, effective, and compliant with global regulatory expectations while supporting continuous improvement and innovation.
ProRelix Research supports the software as a medical device framework by guiding sponsors through clinical strategy development, evidence planning, and regulatory aligned clinical evaluations. With expertise in SaMD clinical trial execution, data management, risk based oversight, and compliant documentation, ProRelix Research helps ensure software products meet global regulatory expectations while maintaining quality, traceability, and patient safety across the entire lifecycle.
Clinical trial evaluation and management for Software as a Medical Device is a structured process to demonstrate safety, performance, and clinical benefit of medical software. Unlike traditional devices, SaMD trials focus strongly on software functionality, clinical relevance, data integrity, and real world usability.
ProRelix Research provides support as a cro for software as medical device clinical trial evaluation and management, assisting sponsors with study planning, clinical evaluation, trial oversight, and regulatory compliant documentation. The focus remains on generating reliable clinical evidence while ensuring quality, compliance, and patient safety throughout the SaMD lifecycle.
Clinical evaluation is the foundation of SaMD approval and adoption. It confirms that the software achieves its intended medical purpose.
Key components include
Clinical evidence generation using literature review, analytical validation, and clinical investigations
Performance evaluation to assess accuracy, sensitivity, specificity, and clinical relevance
Usability and human factors assessment to ensure safe and effective use in real clinical settings
Risk benefit analysis aligned with intended use and patient population
Clinical trials may be prospective, retrospective, observational, or hybrid depending on regulatory expectations and software risk classification.
Effective SaMD trials require tailored study designs that reflect software driven outcomes.
Important considerations
Clearly defined intended use and clinical claims
Appropriate endpoints linked to software outputs
Validation of input data sources and algorithms
Control of bias, version control, and software updates during the study
Robust statistical analysis plan suitable for digital health outcomes
Managing SaMD trials demands strong coordination between clinical, technical, and regulatory teams.
Core management activities include
Study protocol development and regulatory alignment
Site selection and investigator training on software use
Data management and traceability of software versions
Monitoring of trial conduct and data quality
Preparation of clinical study reports and regulatory submissions
Continuous documentation and audit readiness are critical due to evolving regulatory scrutiny of digital health technologies.
Global regulators expect SaMD trials to follow a risk based approach.
Authorities such as FDA, EMA, and IMDRF emphasize
Demonstration of clinical validity
Transparency of algorithms and decision logic
Evidence of ongoing performance monitoring
Alignment with Good Clinical Practice and software lifecycle standards
A Software as a Medical Device (SaMD) clinical trial evaluation tool is a specialized platform or system designed to support the assessment of SaMD products during clinical trials. These tools help collect, organize, and analyze trial data, ensuring the software’s safety, effectiveness, and compliance with regulatory standards.
ProRelix Research provides guidance and support for selecting, implementing, and utilizing Software as a Medical Device clinical trial evaluation tools, helping sponsors streamline trial operations, maintain data integrity, and generate reliable clinical evidence for regulatory submissions.
Capture patient data, software outputs, and real world performance in a secure and traceable manner.
Evaluate accuracy, sensitivity, specificity, and clinical outcomes based on trial endpoints.
Track adverse events, system errors, and software-related risks throughout the study.
Generate audit-ready reports aligned with FDA, EMA, IMDRF, and other regulatory requirements.
Manage software updates and ensure that trial data corresponds to the correct software version.
In clinical trials, Tables, Listings, and Figures (TLFs) are essential for presenting, summarizing, and analyzing study data in a clear, structured, and regulatory-compliant manner. Well-prepared TLFs help sponsors, investigators, and regulatory authorities interpret trial results efficiently, supporting decision-making and approvals.
Tables organize data into rows and columns to summarize key information such as baseline patient characteristics, efficacy outcomes, or adverse events. Listings provide detailed patient-level data for traceability and verification, including lab results, concomitant medications, and adverse events. Figures visually represent trial trends and outcomes, such as line graphs for efficacy over time, bar charts for adverse event distribution, or survival curves for patient outcomes.
ProRelix Research provides expert support in creating high-quality Tables, Listings, and Figures in Clinical Trials, ensuring accuracy, clarity, and compliance with regulatory standards. Whether for regulatory submissions or study analysis, ProRelix Research helps you present clinical trial data with confidence and precision.
Artificial Intelligence (AI) is increasingly being integrated into Software as a Medical Device (SaMD) to improve diagnosis, monitoring, treatment planning, and patient care. AI-SaMD leverages machine learning, deep learning, and other algorithms to analyze complex medical data, detect patterns, and support clinical decision-making.
ProRelix Research provides specialized support for Artificial Intelligence in Software as a Medical Device. We help developers design clinical trials, evaluate AI-SaMD performance, and ensure compliance with global regulatory standards. By assisting with AI-SaMD evaluation, risk assessment, and regulatory documentation, ProRelix Research helps bring safe and effective AI-powered medical software to the market efficiently.
AI algorithms can analyze imaging, lab results, and patient data to assist clinicians in identifying diseases or conditions faster and more accurately.
AI-SaMD can predict patient outcomes, disease progression, or potential adverse events based on historical and real-time data.
AI helps tailor treatment recommendations to individual patients by analyzing data patterns and medical histories.
AI-SaMD can automate repetitive tasks, triage cases, and prioritize clinical interventions to improve efficiency.
AI that adapts or updates over time must ensure safety and effectiveness throughout its lifecycle.
Regulatory authorities require that AI decision-making processes are interpretable and auditable.
AI-SaMD is classified according to the potential impact on patient safety, similar to traditional SaMD, but regulators may require additional evidence due to algorithm complexity.
AI-SaMD must comply with regulations like HIPAA, GDPR, or local healthcare data protection laws.
Software as a Medical Device is software intended to perform medical functions such as diagnosis, monitoring, or treatment without being part of a physical medical device. It can operate independently on computers, mobile devices, or cloud platforms.
Developing SaMD involves defining the intended medical purpose, performing risk classification, following a structured software development lifecycle, implementing quality and risk management systems, conducting clinical validation, and complying with regulatory standards.
Software qualifies as a medical device if it is intended for medical purposes such as diagnosis, monitoring, treatment, or prevention of disease, and if it impacts clinical decisions, patient care, or outcomes. Regulatory authorities like the FDA or EMA provide specific criteria.
A SaMD clinical trial evaluates the safety, performance, and clinical effectiveness of the software in its intended medical context. These trials can be observational, prospective, or hybrid depending on software risk and purpose.
Clinical evaluation ensures that the software achieves its intended medical purpose, produces accurate results, minimizes risk, and meets regulatory compliance for patient safety and effectiveness.
Key steps include defining intended use, risk classification, designing trial protocols, generating clinical evidence, analyzing trial data, monitoring risks, and preparing regulatory-compliant documentation.
Risk classification depends on the software’s potential impact on patient safety and clinical decisions. High-risk software typically requires more extensive clinical evaluation and stricter regulatory oversight.
Evidence can include analytical validation, clinical performance studies, real-world data, usability testing, and risk assessments to demonstrate safety, reliability, and clinical benefit.
Yes, regulatory frameworks from authorities like the FDA, EMA, IMDRF, and ISO standards provide guidance on clinical evidence, risk management, quality systems, and post-market surveillance.
ProRelix Research acts as a CRO for Software as Medical Device Clinical Trial / Evaluation, assisting with study design, clinical evidence generation, trial management, and regulatory documentation to ensure compliance and reliable outcomes.
Bringing new therapies requires accuracy, efficiency, and regulatory care. We offer clinical trial solutions that reduce risk, shorten timelines, and ensure compliance, turning ideas into successful outcomes.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.